8 results about "Mycobacterium smegmatis" patented technology

Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.

This article provides information on mutant single-stranded smegma mycobacterium porin (Msp) and its applications.

This invention provides a method for constructing a high-yield ergothionein-producing Bacillus amyloliquefaciens engineered strain and its application. The engineered strain uses the food-grade safe strain Bacillus amyloliquefaciens HZ12 as the starting strain. Through genetic engineering, a key enzyme gene for ergothionein biosynthesis is heterologously expressed in Bacillus amyloliquefaciens. An RBS co-expression strategy is employed to express the mutant gene NcEgt1 derived from Neurospora crassa. Y174F / E51A Co-expression of the EgtE gene derived from *Mycobacterium smegmatis* successfully achieved heterologous synthesis of ergothioneine in *Bacillus amyloliquefaciens*. Under these conditions, the yield of ergothioneine reached 402.68 mg / L, marking the achievement of ergothioneine production in *Bacillus amyloliquefaciens* from scratch. Subsequently, through chassis strain modification, the yield of ergothioneine was further increased to 690.43 mg / L.

The application discloses a methyl bacillus subtilis sulfoxide synthase MpEgtB mutant and application thereof, and belongs to the technical field of bioengineering. The application provides a methyl bacillus subutilis-derived sulfoxide synthase MpEgtB mutant capable of efficiently preparing ergothioneine and a modification method of the mutant, and the mutant protein is used to catalyze histidine trimethyl inner salt, L-Cys is used as a sulfur donor to directly convert the histidine trimethyl inner salt into histidine trimethyl inner salt-based cysteine sulfoxide, and the obtained mutant is coupled with Mycobacterium smegmatis-derived MsEgtD and MsEgtE to prepare L-EGT by using L-His and L-Met as substrates. The optimal mutant strain is used as a biological catalyst to perform whole-cell conversion, a continuous feeding strategy is adopted in a 5L fermenter, and the conversion is performed for 48h, so that the yield of L-EGT reaches 8.32g / L. The production process is simple, has few impurities, and has an important industrial application prospect.

This invention discloses NmrAL2_Bovine The application of genes as targets in the prevention and control of bovine tuberculosis, including knockout or knockdown. NmrAL2_ Bovine The gene can significantly inhibit the survival of Mycobacterium bovis, Mycobacterium tuberculosis, Mycobacterium bovis BCG, and Mycobacterium smegmae in host cells without affecting the normal proliferation of host cells. Therefore, NmrAL2_Bovine Gene inhibitors can be used to prepare drugs for the prevention and treatment of bovine tuberculosis. NmrAL2_Bovine Genes can also be used as targets in the design of transgenic cattle for breeding against bovine tuberculosis or for genetic therapy research.

This invention belongs to the field of microbiology, specifically relating to the application of albizophenolic compounds. These compounds inhibit pathogenic bacteria such as Salmonella, Mycobacterium smegmatis, Enterococcus faecalis, and Staphylococcus aureus, and inhibit the growth of human lung cancer cells and human breast cancer cells, exhibiting bactericidal and anticancer activities. They are suitable for developing products for everyday household use, medical care, and animal husbandry, with broad prospects for industrial application.

The invention belongs to the technical field of biological medicine, provides a method for constructing a biosafety mouse bone tuberculosis model based on mycobacterium smegmatis, and evaluates that under the condition of a standard biosafety level (BSL)-1, the mycobacterium smegmatis induces local and disseminated bone infection through three infection pathways, and the bone tuberculosis model has the advantages that the bone tuberculosis is induced by the mycobacterium smegmatis through three infection pathways; results show that the mouse model for intracentral injection administration of the three infection pathways is closer to the latent progress of human bone tuberculosis. The mouse model based on the mycobacterium smegmatis provides a simple and reliable platform related to immunopathology for exploring host-pathogen dynamics, immunologically-driven bone destruction and early treatment tests.

The application relates to the field of traditional Chinese medicine against tuberculosis, in particular to a compound extracted from Magnolia officinalis, a preparation method and application of the compound, the compound is shown as formula I, the compound can effectively inhibit the growth of Mycobacterium smegmatis, and can prevent and treat Mycobacterium smegmatis infection, and the MIC of the compound on Mycobacterium smegmatis is 60 ug / mL.